Navigation Links
Moleac Announces Breakthrough Results on Neuroprotective and Neurogenerative Properties of NeuroAiD
Date:2/11/2010

France and Europe shortly on stroke recovery.

David Picard, CEO of Moleac, said "We are extremely enthusiastic and proud to see these data published. It is a strong validation of our research of active ingredients in NeuroAiD as well as of our efforts towards continuous optimization of its formula. These results pave the way for new indications of NeuroAiD beyond stroke recovery such as prevention, cognitive impairments and dementia. It is good news for patients who are in need of treatment in this under-served therapeutic area."

About Moleac

Moleac is a Singapore-based biopharmaceutical company that dedicates itself in finding and developing new medicines for the unmet needs of patients worldwide. http://www.moleac.net

About NeuroAiD

NeuroAiD is a stroke treatment to help stroke patients achieve faster and better recovery. NeuroAiD is derived from natural components, carefully selected for their efficacy and absence of side effects. It currently reaches out to patients in over 25 countries. http://www.neuroaid.com

    Contact details:

     Kasia Kaminska
     Tel: +65-64789432
     
SOURCE Moleac
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Moleac Named Singapore Entrepreneurial Company of the Year at the Frost & Sullivan Excellence in Healthcare Awards
2. Moleac Launches NeuroAid10(TM) in the United States
3. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
4. Kinexus Announces the Launch of a New Protein Kinase Microarray
5. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
6. Tianyin Pharmaceutical Co., Inc. Announces Record Second Quarter 2010 Financial Results
7. Silicon Kinetics Announces New Biosensor Chips With Wide Palette of Surface Chemistries
8. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
9. Healthcare Data Solutions Announces Expansion of its Healthcare Customer Solutions Team With Two Key Additions
10. Angiotech Pharmaceuticals Announces Conference Call and Webcast
11. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... , May 05, 2015 Research ... has announced the addition of the ... to their offering. Macromolecules which ... undergo separation or are broken into smaller ... products. This separation requires various advanced systems ...
(Date:5/5/2015)... DIEGO , May 5, 2015  Renova™ ... for congestive heart failure and other chronic diseases, ... an independent analysis designed to reflect the healthcare ... time. This model will be used to characterize ... CHF, could have on those groups of patients ...
(Date:5/5/2015)... D.C., USA (PRWEB) May 05, 2015 ... regulations covering a wide range of key photonics technologies ... hampering global competitiveness of U.S. industry. To help the ... webinar on 12 May on the proposed changes ... the commodities covered by International Traffic in Arms Regulations ...
(Date:5/5/2015)... FRANCISCO, Calif. , May 5, 2015 ... treatment of cancer, today announced that Sean McCarthy ... the Credit Suisse Antibody Day in New ... May 6. Dr. McCarthy will present an overview of ... and Probody drug conjugate programs. About CytomX ...
Breaking Biology Technology:Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Comments needed now from photonics industry on revisions of U.S. export rules 2Comments needed now from photonics industry on revisions of U.S. export rules 3Comments needed now from photonics industry on revisions of U.S. export rules 4
... 8 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ... and live webcast at 9:00 a.m. Eastern Time on ... financial results.,Michael T. Flavin, Ph.D., Chairman & Chief Executive ... present an update on the Company.,A press release reporting ...
... Calif., Nov. 7 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation ... nine months of 2007 were $6,214,712,an increase of 567% ... Revenues for the third quarter of 2007 were ... third quarter of 2006. These significant,increases are due to ...
... at 1:30 p.m. (Pacific); ... http://www.adventrx.com , SAN DIEGO, Nov. 7 ... and development company,focused on commercializing proprietary product candidates for ... results for,the three-month and nine-month periods ended September 30, ...
Cached Biology Technology:Advanced Life Sciences to Host Third Quarter 2007 Financial Results Conference Call and Live Webcast 2Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 2Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 3Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 4Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 5Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 6Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 7Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 8Kiwa Bio-Tech Third Quarter Revenues Increase 226% - Nine-Month Revenues $6.2 Million 9ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 2ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 3ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 4ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 5ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 6ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 7
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:4/2/2015)... April 2, 2015 According to ... attributed to somewhat higher than 125 MSEK. This exceeds ... report 2014 that revenues for Q1 2015 would be ... reported for Q4 2014. The operating result for the ... The complete interim report will as previously communicated be ...
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... NYU Langone Medical Center,s Departments of Orthopaedic Surgery and ... to detect subtle changes in joint cartilage microstructure ... markers of early osteoarthritis (OA). By using these techniques ... shift the management of the disease from eventual joint ...
... The last century has seen two major pandemics caused ... and 2009,s Swine Flu scare, which had thousands travelling with ... know what distinguished the Swine Flu from ordinary influenza in ... to travel extensively and infect large populations. Until now. ...
... MO, August 15, 2011A compound found in green tea ... treat two types of tumors and a deadly congenital ... led by Principal Investigator, Dr. Thomas Smith at The ... The Children,s Hospital of Philadelphia. Their findings are published ...
Cached Biology News:NYU Langone experts find MRI techniques can detect early osteoarthritis 2Could the Spanish flu devastate us again? 2Researchers demonstrate green tea is effective in treating genetic disorder and types of tumors 2
Polyclonal Antibody to AGAP1 / Centaurin, gamma 2...
Mouse monoclonal [b/e4 (9.20)] to Cytochrome P450 2B1 + 2B2 ( Abpromise for all tested applications)....
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: